Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Gets CE Mark for Intestinal Parasites Test

NEW YORK – Finnish molecular diagnostics company Mobidiag said today that it has received CE-IVD marking for its Novodiag Stool Parasites test for the detection of intestinal parasites from stool samples.

The Novodiag Stool Parasites syndromic test combines real-time PCR and microarray technologies to detect more than 95 percent of intestinal parasites, the firm said. Its test detects the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples.

Espoo, Finland-based Mobidiag said that its test is designed to run on demand using its automated Novodiag platform, which allows direct analysis of a patient sample in a disposable cartridge. The stool parasites test provides results in 90 minutes with less than five minutes hands-on time, and is suitable for use in laboratories and hospitals.

"Parasitic diseases contribute significantly to the burden of infectious diseases worldwide and current diagnostic methods such as microscopy are labor-intensive and require a high level of skill," Mobidiag CEO Tuomas Tenkanen said in a statement.

As the fourth test on the company's platform, Novodiag Stool Parasites joins Novodiag C. difficile, Novodiag Bacterial GE+, and Novodiag CarbaR+ among the company's products.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.